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5.1  Introduction 
Expenditures for health care at the end of life (EOL) have been the object 
of considerable policy interest. To many observers, aggressive health care ad- 
ministered shortly before death is wasteful, at least in retrospect, and there is 
no doubt that elderly Americans use health care heavily before they die. In 
1990, the 6.6 percent of Medicare recipients who died accounted for 22 percent 
of program expenditures (Lubitz and Riley 1993). Some question the benefits 
of such care, especially because severe morbidity and disability may compro- 
mise any years of life potentially gained from such treatments in the very old 
(Verbrugge 1984). The increasing use at advanced ages of costly and aggres- 
sive health interventions, whose impact on both the quality and length of life 
is often unknown, exacerbates these concerns. For example, the use of  radical 
prostatectomy for invasive prostate cancer increased threefold between  1983 
and 1989 (Lu-Yao and Greenberg 1994), and the rate at which both new and 
old major operations are performed in the elderly increased dramatically from 
1972 to  1981 (Valvona and Sloan  1985) and  1984 to  1991 (McClellan and 
Skinner 1994). These phenomena have helped to stimulate a growing literature 
on the significance and policy implications of EOL health care utilization and 
expenditures (Bayer et al.  1983; Lubitz and Prihoda  1984; Scitovsky  1984, 
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1988, 1994; Lubitz and Riley 1993; Schneiderman and Jecker 1993; Emanuel 
and Emanuel 1994). Because nearly all the elderly are insured by  Medicare, 
federal funds pay for most EOL medical costs. 
Despite the provocative findings of this literature, the policy significance of 
EOL care is uncertain. Although they consume a large share of health dollars, 
patients nearing death are not the main source of  large Medicare payments. 
Most high-cost elderly patients are survivors, not decedents. In  1990, for ex- 
ample, the  8 percent  of  Medicare enrollees with over $10,000 in  Medicare 
costs accounted for 65 percent of  all Medicare expenditures. Even if  every 
enrollee who died that year generated more than $10,000 in payments, they 
could have been responsible for at most one-third of this total (Helbing 1993). 
In addition, some studies suggest that the elderly who are most likely to die 
are not responsible for the greatest expenditures; for the very old, for example, 
the ratio of spending for decedents to that for survivors narrows, and more of 
the excess costs are for nursing home care, which presumably is an unavoid- 
able expense (Scitovsky 1988). 
An even more important limitation of an exclusive focus on EOL expendi- 
tures is its implicitly retrospective nature. If health care providers knew ex ante 
which patients would die despite their  interventions, expenditures on dying 
patients could potentially be reduced. Yet often it is impossible, even with de- 
tailed clinical records, to predict  individual patient mortality with sufficient 
specificity to influence medical decision making. Even after days of  detailed 
intensive care unit (ICU) measurements, systems such as APACHE can reli- 
ably predict death in only a small minority of ICU patients (Atlunson et al. 
1994), and such systems have not been shown to lead to more cost-effective 
decisions than expert physicians would otherwise make. Furthermore, specific 
policies designed to reduce EOL expenditures, such as advance directives and 
“do not resuscitate” orders, seem to have had only a modest impact on overall 
expenditures. As a result, some analysts have recently argued that attempts to 
limit EOL expenditures through both of these methods are unlikely to reduce 
health expenditures substantially (Emanuel and Emanuel 1994). Simpler ra- 
tioning rules, such as age-based rationing of costly operations or ICU admis- 
sions, are even less likely to lead to selective reductions in “futile” care, since 
there are no simple characteristics such as age or disease that clearly predict 
whether interventions are likely to be worthwhile. 
Moreover, such rationing  rules  would have large effects on expenditures 
only if implemented at ages when life expectancy remains substantial, such as 
below age 70 (Garber and Fuchs  1992). Finally, some of  the expenditures at 
the end of  life are for treatments designed to provide comfort rather than to 
prevent death. Refinements in methods to predict death and avoid inappropri- 
ately aggressive care would not reduce these expenditures. 
Although there is growing disenchantment with policies designed to identify 
and avert “futile care” at the  individual patient  level, the consequences  of 
population-level policies merit further exploration. Little is known about the 249  Diagnosis and Medicare Spending at the End of Life 
impact on the cost and outcomes of elderly populations with major illnesses 
of  policies  that  would  lead to a generally  more parsimonious  approach  to 
health care delivery. Would efforts designed to limit major operations, aggres- 
sive diagnostic approaches, or care delivered in ICUs lead to an increase in 
mortality rates, health complications, and other adverse outcomes in the popu- 
lations with major illness? Would substantial cost savings result from associ- 
ated reductions in technology use? Further analysis of alternative patterns of 
care for severe illness might also reveal why policies designed to reduce EOL 
expenditures have had such disappointing results. Perhaps decedents consume 
substantial care because it is not clear until very late in the course of their 
illnesses that they will die. Even if  they are known to suffer from illnesses 
that are nearly always fatal, it may be neither feasible nor desirable to reduce 
expenditures for their health care. For example, advance directives may  not 
save money because they induce the substitution of one set of services (such 
as nursing home or hospice care) for another (hospital care), because high- 
intensity care at the end of life does not prolong life for long enough to gener- 
ate large increases in expenditures, or because intensive spending is already 
concentrated on treatments that have a significant chance of  improving out- 
comes. 
As a first step toward addressing these questions, we sought to explore the 
basic characteristics of Medicare recipients during the time approaching their 
deaths. The magnitude of health expenditures for Medicare enrollees with ma- 
jor illnesses and uncertainty about their impact on costs and outcomes under- 
scores the need for basic information about the prevalence, causes, and con- 
comitants  of  the conditions that  commonly  lead  to  death  among  the  US. 
elderly. What characteristics of patients are associated with high-cost care and 
high probability of death? Can these characteristics be used to identify individ- 
uals and populations with major illnesses prospectively, to guide policies on 
the use of intensive treatments? What is the distribution of costs and survival 
across high-risk illnesses, and across individuals with a given illness, and how 
are they correlated? In this study, we report the results of analyses of expendi- 
tures patterns for Medicare decedents, investigating in particular the diseases 
and demographic characteristics of decedents and the associated Medicare ex- 
penditures. 
5.2  Analytic Data Files 
Our analysis builds from linked Medicare Part A (hospital) and Part B (phy- 
sician and other services) claims files. These files include information regard- 
ing all covered services (inpatient, hospital outpatient, ambulatory and physi- 
cian care, durable medical equipment, home care, hospice care, and skilled 
nursing and rehabilitation care), key discharge information (discharge destina- 
tion and condition), and demographic information (including residence infor- 
mation at the zip code level). Demographic information is updated annually. 250  Alan M. Garber, Thomas MaCurdy, and Mark McClellan 
Failure to meet deductible or out-of-pocket limits for the year will rarely lead 
to omission of significant utilization data in the major illness population that 
we study. EOL Medicare expenditures and disease incidence figures are calcu- 
lated from patients  in the Medicare 5  percent  beneficiary  sample (obtained 
from the Health Care Financing Administration  [HCFA]) who died between 
1986  and 1990 and who also received inpatient treatment for cancer, cardiovas- 
cular, cerebrovascular, “fatal,” or “frailty” disorders during the last year of their 
lives. The specific diagnostic groupings are based on an aggregation scheme 
developed  by  McClellan  to map primary diagnosis codes into one of  155 
disease  groupings.  In this approach, a  “cancer patient”  is someone who,  at 
any point during the last year of life, was admitted  to a hospital with a pri- 
mary  diagnosis of  oropharyngeal,  upper  gastrointestinal,  colorectal,  intra- 
abdominal, upper respiratory tract, lung, thoracic, bone/connective tissue, skin, 
breast, genital, prostate, central nervous system, or other primary solid cancers; 
secondary  solid cancer/metastasis;  leukemia/lymphoma; or malignancies  of 
the bladders, kidneys, or urinary tract. Similarly, anyone with a primary diag- 
nosis of acute myocardial infarction, old myocardial infarction, ischemic heart 
disease, cardiac valve disorders, cardiac conduction  defects, cardiac arrhyth- 
mia, ventricular arrhythmia, supraventridunspecified arrythmia, atrial fibrilla- 
tion, or heart failure is a “cardiovascular patient.” “Cerebrovascular patients” 
are those with a primary  diagnosis of  hemorrhagic  stroke, occlusive stroke, 
transient cerebral ischemia, or chronic cerebrovascular deficits. “Fatal” disor- 
ders are colorectal  cancer,  lung cancer,  breast cancer, prostate  cancer, acute 
myocardial  infarction,  ischemic  heart  disease, ventricular  arrhythmia,  heart 
failure, occlusive  stroke,  chronic  obstructive  pulmonary  disease  (which in- 
cludes chronic bronchitis,  emphysema, and some forms of  asthma), and hip 
fracture.  Finally,  the “frailty”  conditions we consider  are septicemia,  endo- 
crine/metabolic disorders (except diabetes), pneumonia, pyelonephritis, cysti- 
tis/lower urinary tract infections, and failure to thrive/malnutrition. (For each 
of tables 5.1  1 through 5.13, below, the percentage in the upper left-hand comer 
indicates  the  percentage of  those who died who  fall  into these  diagnosis 
groupings.) 
We  merge the Part A (MEDPAR), Part B (BMAD), and outpatient (OUT- 
PAT)  files to calculate  total Medicare reimbursements  for each patient  dur- 
ing the indicated periods. For Part A and outpatient claims, we use the HCFA 
reported reimbursement amounts. For a Part B claim, reimbursed amounts are 
calculated as 0.8 times allowed charges. All claims are deflated to 1990  dollars 
by the CPI. We sum these three components to calculate total reimbursements 
for each person during the period. The “Percentage of Total Medicare Expendi- 
tures” sums total reimbursements  for the group and expresses this sum as a 
fraction of total reimbursements for all patients in the HCFA 5 percent sample 
from 1986-90.  Thus the cost figures reported  are based on reimbursements 
and do  not include the patient’s out-of-pocket expenditures for noncovered ser- 
vices, copayments, or deductibles. 251  Diagnosis and Medicare Spending at the End of Life 
To calculate disease incidence among the group in any time period, we count 
by  disease type all primary  diagnoses of beneficiaries  in the specified  sub- 
sample during that time period, rank the diseases, and report the 14  most preva- 
lent as percentages. In other words, the 28.1 percent number reported in table 
5.12 for heart failure during the last year of  life for cardiovascular  patients 
means:  of all the hospital admissions for cardiovascular patients during the 
last year of  life, 28.1 percent of the admissions had a primary diagnosis of 
heart failure. 
Sample selection is based on gender and age during the year that the patient 
dies. As a means of  summarizing the presentation efficiently, we allocate age 
at death into three categories: 65-74,75-84,  and 85-99.  It bears repeating that 
there are a few sample restrictions that we place on every analysis we do. To 
be in any of  our tables, patients must be between the ages of 65 and 99. We 
also exclude all prior or current HMO members. 
5.3  Results 
Table 5.1 shows basic characteristics of Medicare beneficiaries who die. Ap- 
proximately  15 percent of  all Medicare beneficiaries  will die in  a five-year 
period. As the age and sex distribution of decedents shows, women tend to be 
Table 5.1  Characteristics of Medicare Beneficiaries Who Die, 1986-90 
Characteristic  Percentage 
Age and Sex Distribution  (% Male/% Female) 
65-69  1.915.4 
70-14  9.111.1 
1  5-1 9  10.4l9.11 
80-84  9.0110.3 
80-84  9.0110.3 
85-89  6.2110.1 
90-100  4.2110.6 
Racial Distribution (%) 
White  89.0 
Black  8.2 
Asian  1.1 
Percentage of Benejiciaries  Who Die Each Year 
1986  4.59 
1987  4.58 
1988  4.61 
1989  4.61 
1990  4.54 
1986-90  15 252  Alan M. Garber, Thomas MaCurdy, and Mark McClellan 
somewhat older  when  they  die than  men, and deaths  are distributed fairly 
evenly over the five-year age intervals. Approximately 90 percent of all dece- 
dents  are white,  the  rest  being  predominantly  black. A high  percentage- 
roughly  5 percent-of  all Medicare beneficiaries die each year, greatly ex- 
ceeding the annual mortality rates for other segments of the population. 
Table 5.2, which reports overall Medicare expenditures before death, shows 
that the vast majority  of  Medicare recipients have claims in the year before 
they die. Only about 4 percent do not have claims. The mean expenditures in 
the last year of  life over the  1986-90  period total about $13,000, more than 
half of  which occurred in the last three months of life. The 50th percentile, 
however, is only about $8,000 in the last year of life, reflecting the influence 
of the upper tail of the distribution of expenditures, which can reach very large 
amounts. Reimbursements of $8,000 can easily be incurred in a single hospi- 
talization. 
Panel B of table 5.2 shows the percentage of deaths associated with several 
of the most common diagnoses. These are expressed in three ways. The column 
labeled “first” gives the percentage of times the given diagnosis was listed as 
the primary diagnosis during the first hospital admission of the year of death. 
“Last” refers to the same figure, except for the final admission during the year, 
rather than the first. To the extent that patients have a single hospital admission 
during the last year of life, these figures should be similar. The columns labeled 
“all year” and “all period” refer to the percentage of times the given diagnosis 
was the  principal  diagnosis during any  admission during the corresponding 
time period. 
For most diagnoses, it does not matter which of these definitions of preva- 
lence is used. Among the exceptions to this general observation are conditions 
that cause death in elderly women who are already chronically ill with one or 
more other diseases. For example, in the last year of life, the prevalence  of 
pneumonia as a diagnosis rises from 5.61 percent as initial diagnosis to 7.07 
percent if the final diagnosis is the basis for the prevalence estimate. Similarly, 
the percentage of deaths attributable to septicemia nearly doubles if the final 
admission is the basis for the diagnosis. Some other diagnoses, such as hip 
fracture, are more common as first than as last diagnoses. The shifts in rankings 
reflect the characteristics of these disorders. Septicemia, which refers to dis- 
seminated bloodstream infection, ordinarily causes death in the setting of one 
or more other chronic diseases and would more often be the final blow that 
fells a severely ill man or woman than a deadly disease occurring in isolation. 
Pneumonia is another condition that frequently causes death when associated 
with multiple other chronic diseases or a general state of debilitation. This is 
particularly true of aspiration pneumonia, which is caused by inability to swal- 
low and cough appropriately. It is often the final cause of death in individuals 
suffering from stroke, Alzheimer’s disease, prolonged mechanical ventilation, 
and numerous other conditions that depress neurological  or respiratory func- 
tion. Pneumonia, septicemia, and related conditions can indeed cause death, Table 5.2  Medicare Expenditures and Diagnoses for the Elderly during Periods before Death, 1986-90 
A. Expenditures before Death 
Last Year of  Life  Last Six Months  Last Three Months 
Fraction without 
Expenditures within group (1990 $) 
expenditures (%)  3.68 
10th Percentile  350.03 
25th Percentile  3,161.2  1 
50th Percentile  8,386.09 
75th Percentile  17,418.53 
90th Percentile  29,744.18 
Mean  12,833.99 
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(continued) Table 5.2  (continued) 
B. Percentages of Deaths Associated with Most Prevalent Diagnoses“ 
Last Three Months  Last Year of Life  Last Six Months 









Ischemic heart disease 
Hip fracture 
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Acute respiratory failure 



































































































































““First”  (“last”) refers to the primary diagnosis associated with the first (last) hospital admission reported in the specified period, and “all year” (or “all period”) refers 
to the average number of times the diagnosis is reported as the primary diagnosis for all hospital visits during period. 255  Diagnosis and Medicare Spending at the End of Life 
yet  prevention  or successful  treatment of these conditions, because they  so 
frequently occur as complications of other severe illnesses, might not prolong 
survival substantially. 
No single condition stands out as a dominant cause of death among Medi- 
care recipients. Only two diagnostic categories account for more than 6 percent 
of the deaths in any of the time periods, and the single most common diagnosis 
for any of the time periods before death is pneumonia, which only reaches a 
prevalence of 7.07 percent as the last listed diagnosis in the last year of life. 
Congestive heart failure, the most prevalent  diagnosis in the last year of  life 
under most definitions, is a disorder of highly variable severity. Under some 
circumstances, it can be rapidly fatal, but more often, it is a chronic disease 
with a moderately high mortality rate. It often occurs in association with acute 
myocardial infarction, or with a diagnosis of coronary artery disease. But its 
frequency as a cause of death may reflect the high prevalence of the disorder 
rather than a very high mortality rate. 
Tables 5.3 through 5.10 present similar figures for the following groups: all 
women, all men, women in three different age groups, and men in three differ- 
ent age groups. These tables demonstrate that women have causes of death that 
are broadly similar to those of men, with an upward shift in the age distribu- 
tion. Of  course, there  are obvious exceptions, such as some of  the cancers. 
There are also distinct age trends in the prevalence of differing causes of death. 
As  tables 5.3 (women) and 5.4 (men) demonstrate, overall Medicare expen- 
ditures in the periods before death are similar for men and women. About half 
of the expenditures are for Part A, and median expenditures in the last year of 
life are somewhat higher  than $8,000 for both  men  and  women.  Similarly, 
mean expenditures are between $12,000 and $13,000. The two genders display 
similar trends of increasing use of resources as death approaches, as can be 
seen in the shorter intervals before death represented as one moves to the right 
on each of  these tables. The prevalences  of  specific causes of  death are also 
similar. However, men are much more likely to die of  lung cancer, reflecting 
the greater prevalence of  this disease in current cohorts of the elderly, while 
hip fracture is much more common among women. 
Some of the differences in the prevalences of disorders may also reflect dif- 
ferences in the distribution  of age at death. Because women  survive longer 
than men, disorders that are common in far advanced age, such as hip fracture, 
are more likely to be a cause of  death in women. Some hints of this phenome- 
non can be  seen  in the results  stratified by  age, which appear in tables 5.5 
through  5.10. Tables 5.5, 5.6, and 5.7 give EOL expenditures and diagnoses 
for women in the 65-74,75-84,  and 85-99  age ranges, respectively. Tables 5.8, 
5.9, and 5.10 give results for men in the same age categories. A comparison of 
the tables  for women  shows that median  Medicare expenditures  in  the  last 
year of life, and in the shorter intervals before death, decline substantially with 
advancing age, from about $11,000 for ages 65-74  to less than $6,000 for ages Table 5.3  End-of-Life Medicare Expenditures and Diagnoses for All Women Aged 
65-99,1986-90 
A. Expenditures before Death 
Last Year  Last Three 
of Life  Last Six Months  Months  Last One Month 
Fraction without 
Expenditures within group 
expenditures (70)  2.5 
(1990 $) 
10th Percentile  401.11 
25th Percentile  3,185.39 
50th Percentile  8,022.81 
75th Percentile  16,445.12 
90th Percentile  28,087.96 
Mean  12,241.14 
Percentage of total 
Medicare 
expenditures due 
to category  12.0 
Percentage 
hospitalized  77.8 
3.3  4.1  9.0 
175.85 
1.666.49 
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B. Percentages of Deaths Associated with Most Prevalent Diagnosesa 
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"See table 5.2 note. Table 5.4  End-of-Life Medicare Expenditures and Diagnoses for All Men Aged 
65-99,198690 
A. Expenditures before Death 
Last Year  Last Three 
of Life  Last Six Months  Months  Last One Month 
Fraction without 
expenditures (%) 
Expenditures within grc 
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67.1  59.2 
B. Percentages of Deaths Associated with Most Prevalent Diagnoses* 










































































"See table 5.2 note Table 5.5  End-of-Life Medicare Expenditures and Diagnoses for Women Aged 
65-74,198690 
A. Expenditures before Death 
Last Year  Last Three 
of Life  Last Six Months  Months  Last One Month 
Fraction without 
Expenditures within group 
expenditures (%)  4.7 
(1990 $) 
10th Percentile  43 1.77 
25th Percentile  4,504.67 
50th Percentile  11,453.55 
75th Percentile  22,387.00 
90th Percentile  36,636.28 
Mean  16,354.99 
Percentage of  total 
Medicare 
expenditures due 
to category  3.8 
hospitalized  81.1 
Percentage 
5.5  6.3  10.8 
183.23 
3,178.22 
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5ee  table 5.2 note. Table 5.6  End-of-Life Medicare Expenditures and Diagnoses for Women Aged 
75434,1986-90 
A. Expenditures before Death 
Last Year  Last Three 
of Life  Last Six Months  Months  Last One Month 
Fraction without 
Expenditures within group 
expenditures ('3%)  1.8 
(1990 $) 
10th Percentile  615.44 
25th Percentile  3,970.87 
50th Percentile  9,134.01 
75th Percentile  17,626.68 
90th Percentile  29,344.14 
Mean  13,175.82 
Percentage of  total 
Medicare 
expenditures due 
to category  4.8 





























B. Percentages of Deaths Associated with Most Prevalent Diagnosesa 
Primary Diagnosis  All Year  All Period  All Period  All Period 
Heart failure 
Pneumonia 
8.7  9.0  9.1  9.0 
6.3  6.8  7.3  7.8 
Acute myocardial 
infarction  6.2  7.1  7.6  8.5 
Occlusive stroke  6.2  6.6  6.7  7.0 
Secondary solid 
cancerhetastasis  4.0  4.9  5.2  5.1 
Metabolic disorders  3.6  3.8  3.8  3.8 
Lung cancer  I .8  I .9  2.0  2.0 
Ischemic heart 
disease  2.6  2.2  2.0  1.7 
Hip fracture  2.7  2.4  2.2  2.0 
Septicemia  2.2  2.6  3  .O  3.5 
failure  2.1  2.5  2.8  3.3 
urinary tract 
infection  2.2  2.2  2.2  2.0 
Intestinal diseases  2.4  2.4  2.4  2.4 
Colorectal cancers  1.9  1.7  2.0  1.6 
'See  table 5.2 note. 
Acute respiratory 
Cystitis/lower Table 5.7  End-of-Life Medicare Expenditures and Diagnoses for Women Aged 
85-99,1986-90 
A. Expenditures before Death 
Last Year  Last Three 
of Life  Last Six Months  Months  Last One Month 
Fraction without 
Expenditures within group 
expenditures (%)  1.8 
(1990 $1 
10th Percentile  307.03 
25th Percentile  1,798.76 
50th Percentile  5,857.67 
75th Percentile  12,172.60 
90th Percentile  20,463.42 
Mean  8,874.33 
Percentage of total 
Medicare 
expenditures due 
to category  3.4 
Percentage 
hospitalized  72.5 



















2.7  2.2 
61.3 
1.5 
66.7  52.8 
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B. Percentages of Deaths Associated with Most Prevalent Diagnosesa 







































































3.  I 
2.6 
1.1 
'See table 5.2 note. Table 5.8  End-of-Life Medicare Expenditures and Diagnoses for Men Aged 
65-74,198690 
A. Expenditures before Death 
Last Year  Last Three 
of Life  Last Six Months  Months  Last One Month 
Fraction without 
Expenditures within group 
expenditures (%)  9.5 
(1990 $1 
10th Percentile  25.44 
25th Percentile  1,609.77 
50th Percentile  8,707.63 
75th Percentile  19,775.05 
90th Percentile  34,208.76 
Mean  14,035.7s 
Percentage of total 
Medicare 
expenditures due 
to category  4.6 
hospitalized  72.4 
Percentage 
















15,4  18.45 
26,970.12 
l0,95  1.27 
3.6 





B. Percentages of Deaths Associated with Most Prevalent Diagnosesa 










































































&See  table 5.2 note. Table 5.9  End-of-Life Medicare Expenditures and Diagnoses for Men Aged 
75-84,1986-90 
A. Expenditures before Death 
Last Year  Last Three 
of Life  Last Six Months  Months  Last One Month 
Fraction without 
Expenditures within group 
expenditures (9'0)  3.4  4.4  5.4  10.4 
(1990 $) 
10th Percentile  455.60  201.80  102.81  0 
25th Percentile  3,701.15  2,432.73  1,186.08  245.34 
50th Percentile  9,090.48  6,667.19  5,298.82  3,665.82 
75th Percentile  18,091.57  14,026.89  11,213.21  7,156.25 
30,197.42  23,889.06  19,361.26  13,925.42  90th Percentile 
Mean  13,370.19  10,419.25  8,495.22  5,853.86 
Percentage of total 
Medicare 
expenditures due 
to category  4.8  3.8  3.1  2.1 
Percentage 
hospitalized  79.8  75.0  70. I  61.9 
B. Percentages of Deaths Associated with Most Prevalent Diagnosesd 














































































'See  table 5.2 note Table 5.10  End-of-Life Medicare Expenditures and Diagnoses for Men Aged 
85-99,198690 
A. Expenditures before Death 
Last Year  Last Three 
of Life  Last Six Months  Months  Last One Month 
Fraction without 
Expenditures within group 
expenditures (%)  2.9 
(1990 $1 
10th Percentile  351.14 
25th Percentile  2,908.81 
50th Percentile  6,816.93 
75th Percentile  13,637.80 
90th Percentile  22,748.42 
Mean  10,061.70 
Percentage of total 
Medicare 
expenditures due 
to category  2.0 






10,7  15.2  1 
18,461.93 
































All Year  All Period  All Period  All Period 
8.9  9.4  9.5  9.5 
12.4  13.8  14.5  15.6 
4.6  5.1  5.4  6.0 
5.7  6.0  6.1  6.2 
1.8  2.3  2.3  2.3 
4.3  4.6  4.7  4.7 
1.1  1.2  1.2  1.2 
Ischemic heart 
disease  1.8  1.5  I .3  1.1 
Hip fracture  3.5  3.4  3.2  2.9 
Acute respiratory 
Cystitisflower 
Septicemia  2.6  3.1  3.4  3.7 
failure  1.3  1.7  1.9  2.4 
urinary tract 
infection  2.7  2.7  2.5  2.4 
Intestinal diseases  1.8  1.7  I .7  1.7 
Colorectal cancers  1.4  1.3  1.3  1.3 
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85-99.  Mean expenditures also drop, from $16,000  to $9,000. Similar declines 
with age are seen using different time periods-the  last six months, the last 
three months, and the last one month-instead  of the last year of life. 
The diagnoses associated with death also show a distinct age trend. Heart 
failure becomes an increasingly common cause of death as age advances, and 
the same is true of pneumonia and occlusive stroke. Secondary solid cancer/ 
metastasis and lung cancer become less common with advancing age as causes 
of death, as does acute respiratory failure. 
Mean Medicare expenditures in the last year of life do not decline as much 
for men as for women, and median expenditures in the last year of life decline 
from about $9,000 in men aged 65-74  to $7,000 in men aged 85-99,  a less 
dramatic decline than for women. A higher fraction of men aged 65-74  than 
women of the same ages die without having Medicare reimbursements in the 
last year of life, possibly  reflecting  the influence  of sudden and unexpected 
deaths that are more likely at the earlier ages than at far advanced ages. The 
prevalence of congestive heart failure as a cause of death does not rise as rap- 
idly for men as for women, but pneumonia and septicemia do become consid- 
erably more common at the most far advanced ages, while lung cancer and 
other cancers decline in prevalence as causes of death at the far advanced ages. 
The most dramatic age-related increase in prevalence is for hip fracture, rising 
from 0.6 percent in the last year of life for men aged 65-74  to 3.5 percent for 
men aged 85-99. 
These figures provide few surprises about the causes of death, but they dem- 
onstrate that the most common causes of death are the most prevalent chronic 
diseases among the  elderly, rather than  diseases that have intrinsically  very 
high mortality rates. Furthermore, it appears likely that some of the causes that 
are acute, such as pneumonia  and septicemia, cannot always be anticipated, 
and at the time of onset of these conditions, dramatic reductions in expendi- 
tures may not be possible, because the time until death is fairly short. 
Further evidence about EOL expenditures for individuals with specific dis- 
eases appears in tables 5.11 through 5.13. Table 5.11 presents findings similar 
to those of the previous tables, except that only men and women with a princi- 
pal diagnosis of a common cancer during the last year of life are included. The 
fraction of  decedents who did not have Medicare expenditures in the last year 
of life appears in the first row, which shows that it is a rare phenomenon. How- 
ever, more than 5 percent have no expenditures in the last month, perhaps be- 
cause many were not hospitalized and received little medical care during the 
terminal phases of their illnesses. Mean expenditures in the last year of life for 
cancer decedents approach $20,000, a fairly high number, but expenses tend 
to be lower in the last month of life than for many other conditions. 
Panel B of table 5.11 shows the prevalence of different diagnoses listed dur- 
ing hospital admissions of enrollees with cancer during the last year of  their 
lives. Not surprisingly, most of the diagnoses are of cancers. But other common 
conditions also appear in the list of leading diagnoses, such as pneumonia and Table 5.11  Medicare Expenditures and Diagnoses for Patients Admitted with Cancer 
in Last Year of Life, 198690 
A. Expenditures before Death 
Last Year  Last Three 
17.1  % of Deaths  of Life  Last Six Months  Months  Last One Month 
Fraction without 
Expenditures within group 
expenditures (%)  0.1 
(1990 $) 
10th Percentile  5,732.81 
25th Percentile  9,799.36 
50th Percentile  16,086.52 
75th Percentile  24,920.66 
90th Percentile  36,127.09 
Mean  19,349.31 
Percentage of  total 
Medicare 
expenditures due 
to category  6.2 



















4.7  3.6  2.2 
8.  Percentages of  Deaths Associated with Most Prevalent Diagnoses” 











































































Note: “Cancer” includes admissions with the following principal diagnoses: oropharyngeal cancer, upper 
gastrointestinal cancer, colorectal cancer, intra-abdominal cancer, upper respiratory tract cancer, lung can- 
cer, other respiratory tract cancer, thoracic cancer, bone/connective tissue cancer, skin cancer, breast can- 
cer, genital cancer, prostate cancer, central nervous system cancer, bladder cancer, kidney cancer, urinary 
tract cancer, leukemidymphoma, and secondary solid cancer/metastasis. 
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metabolic disorders, which can be complications of cancer, and heart failure, 
which is less frequently a complication. Because heart failure is so common at 
advanced ages, it may have been an unrelated coexisting disorder in many of 
the Medicare recipients  who had cancer. Thus just under 60 percent  of the 
diagnoses in the last year of life were of a common form of cancer. The re- 
maining 40 percent were a combination  of complications, coexisting condi- 
tions that may have been unrelated, and less common cancers. 
Table 5.12 reports analogous findings for decedents with cardiovascular dis- 
eases. These diseases as a group were somewhat less expensive than the can- 
cers. The diagnoses listed as most prevalent are primarily subsets of cardiovas- 
cular diseases.  However, other common acute and chronic  conditions (e.g., 
pneumonia, metabolic disorders, chronic obstructive pulmonary disease, intes- 
tinal diseases, cystitis, and septicemia) listed as leading diagnoses during the 
last year of life are not cardiovascular diseases and may only be related insofar 
as the cardiovascular diseases can be debilitating. For example, a patient who 
suffers a stroke-which  is a form of cardiovascular disease-may  develop a 
partial paralysis, which can subsequently lead to skin breakdown, wound infec- 
tion, and septicemia. Thus a cardiovascular disorder can lead to debilitation, 
which in turn predisposes the patient to an “unrelated” infectious condition. 
Septicemia is one of  the chronic disorders that we refer to as “frailty dis- 
eases” (see table 5.13). This is a loosely grouped set of  diagnoses that can be 
considered markers for debility or, in the case of malnutrition and failure to 
thrive, debilitating conditions in their own right. Most often the elderly Medi- 
care enrollees who are admitted to hospitals with one of these diagnoses have 
multiple chronic health problems. All of these patients have at least one hospi- 
tal admission during the  last year of life, and mean  Medicare expenditures 
for their care is similar to the mean for cancers and cardiovascular diseases. 
Pneumonia is the most prevalent diagnosis in this group, presumably because 
it is one of the most common of the frailty diseases and because it often coex- 
ists with other frailty diseases. 
All of the preceding tables describe characteristics of decedents. Table 5.14 
presents information about the importance of decedents within the population 
of  high-cost  Medicare  enrollees.  Several  categories  of  high-cost  users  are 
listed in the column headings-those  who have the highest 2 percent of expen- 
ditures in a given year, the top decile, and the top two deciles over varying 
periods. Note that about 20 percent of  all beneficiaries  in a five-year period 
will be in the top decile during one year. Note also that a relatively high fraction 
of the high-cost users die during the relevant time period, and that those who 
are most consistently high-cost users (top 2 percent during a year, top decile 
in any year, top two deciles in any two years) have mortality rates approaching 
one-third, but that all of the high-cost users have high mortality  rates. Mean 
expenditures are highest for those in the top 2 percent, at more than $33,000 
per year, but the top decile has mean expenditures of more than $17,000. This 
figure is similar to the mean expenditures for the decedents, even though most Table 5.12  Medicare Expenditures and Diagnoses for Patients Admitted with 
Cardiovascular Diseases in Last Year of Life, 1986-90 
A. Expenditures before Death 
Last Year  Last Three 
22.1  % of Deaths  of Life  Last Six Months  Months  Last One Month 
Fraction without 
Expenditures within group 
expenditures (%)  0.1 
(1990 $) 
10th Percentile  4,254.72 
25th Percentile  6,624.80 
50th Percentile  12,361.06 
75th Percentile  22,403.30 
90th Percentile  36,5 19.65 
Mean  17,458.70 
Percentage of total 
Medicare 
expenditures due 
to category  7.2 



















5.5  4.4  3.1 
B. Percentages of Deaths Associated with Most Prevalent Diagnosesa 



















28. I  28.5  28.4  27.4 





















2. I  2.0  1.8  I .7 
1.6  1.7  1.8  1.9 
1.1 








infection  1  .o  0.9  0.9  0.7 
respiratory 
disease  1 .o  0.8  0.7  0.4 
Septicemia  0.9  1  .o  1.1  1.3 
Note: “Cardiovascular diseases” includes admissions with the following principal diagnoses: acute myo- 
cardial infarction, old myocardial infarction, ischemic heart disease, cardiac valve disorders, cardiac con- 
duction defects, supraventric/unspecified arrhythmia, atrial fibrillation, cardiac arrhythmia, ventricular 
arrhythmia, and heart failure. 
‘See table 5.2 note. 
Acute upper Table 5.13  Medicare Expenditures and Diagnoses for Patients Admitted with “Frailty” 
Diseases in Last Year of Life, 1986-90 
A. Expenditures before Death 
Last Year  Last Three 








































7.4  5.6  4.3  2.7 
B. Percentages of Deaths Associated with Most Prevalent Diagnoses” 



























































1.4  1.1  0.8  0.6 
1.4  1.2  1  .o  0.7 








1  .o 
Nore; “Frailty” includes admissions with the following principal diagnoses: septicemia, endocrine/meta- 
bolic disorders, pneumonia, pyelonephritis, cystitishower urinary tract infections, and failure to thrive/ 
malnutrition. 
‘See table 5.2 note Table 5.14  High-Cost Users of Medicare and Their Share of Reimbursements 
Intensity and Duration of  Utilization 
Top 2% in 
Any Year 
Top Decile in  Top Decile in  Top 2 Deciles in 
Any Year  Only One Year  Any Two Yearsd 
Top 2 Deciles in 
Any Three Years;' 
Top 2 Deciles in 
Any Four Yearsd 
Percentage of  all 
beneficiaries 
Percentage who die 










Expenditures within group 
























30.0 1  20.97  16.51 
27.8 
6.116.0 









25.03  33.2 
and Sex Distribution (% Male/%  Female) 
6.916.6  4.414.7 
I1.1111.1  10.911  1.6 
10.6111.9  11.4112.9 
7.9110.8  8.6112.1 
4.818.4  5.019  .O 
2.8717.18  2.716.6 
88.9  88.9 
7.3  7.8 
1.4  1.3 
Racial Distribution  (%) 
Expenditures before Death 
7,604.16  7,3  3 8.5  9  6,403.  I1 
9,369.49  8,661.23  7,872.77 
13,204.98  11,682.84  10,972.00 
20,398.70  17,472.55  16,389.00 
3 I ,018.88  26,947.36  23,797.24 


































12,429.  I5 
(continued) Table 5.14  (continued) 
Intensity and Duration of Utilization 
Top 2%  in  Top Decile in  Top Decile in  Top 2 Deciles in  Top 2 Deciles in  Top 2 Deciles in 
Any Year  Any Year  Only One Year  Any Two Years”  Any Three Years.’  Any Four Yearsd 
Percentage of total 
Medicare 
expenditures due to 
category 
Heart failure 



















25  52.79  32.42  46.19 
4.41  4.05  5.39 
6.19  6.00  5.72 
4.21  4.12  4.67 
4.08  4.40  3.87 
Percentage of Deaths Associated with Most Prevalent Diagnoses 

















3.88  4.26 
2.37  2.23 












1.78  1.68 







1.06  1.12  1.05  1.46  I .64  I .66 
0.74 
2.17 
0.86  0.70 
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of the high-cost users did not die. The distribution of prevalent  diagnoses is 
broadly  similar to the distribution for decedents, except that ischemic heart 
disease is responsible for a disproportionate share of expenditures among the 
top 2 percent. 
5.4  Conclusions 
The results reported here are among the preliminary findings from a study 
of Medicare expenditures for the care of the severely ill elderly. The limitations 
of Medicare claims files, which constitute the primary data source for this re- 
search effort, are well known: the reliability of some of the diagnostic coding 
is uncertain, there is little clinical detail, there is no information about noncov- 
ered services (such as outpatient pharmacy use and many forms of long-term 
care),  and detailed socioeconomic  characteristics  (such  as income, occupa- 
tional or educational history, and living arrangements) are not recorded. But 
the claims files have many advantages for descriptive analyses of health expen- 
ditures and other phenomena at the end of life. They include a representative 
sample of all elderly Americans, the diagnostic codes are likely to be reason- 
ably accurate guides to the overall prevalence of  various health conditions at 
death, and they include information about virtually all hospitalizations and of- 
fice visits among Medicare recipients. 
Because the data analyzed here are from the late 1980s, few Medicare pa- 
tients were enrolled in HMOs or covered by capitated contracts. Thus our anal- 
ysis does not address current concerns that incentives to limit costs and utiliza- 
tion under managed care might lead to undertreatment of Medicare recipients. 
Our planned analyses of more Medicare data from the 1990s will investigate 
these issues, which are of particular concern for the most vulnerable Medicare 
recipients-those  with chronic or severe illnesses. Under Medicare’s tradi- 
tional fee-for-service reimbursement arrangements, such patients generated a 
high level of utilization, which often meant substantial revenues for physicians 
and possibly for hospitals (Medicare’s Prospective Payment System, which re- 
imburses hospitals a fixed amount per admission, makes hospital incentives 
ambiguous). Under capitation, such patients are undesirable. Because the al- 
tered incentives may have their most prominent manifestations in care adminis- 
tered near the end of life, comparisons of care for decedents between managed 
care and fee-for-service based on recent data may be illuminating. 
Like previous investigators, we found that Medicare expenditures for dece- 
dents decline with advancing age. Health expenditures not covered by Medi- 
care, such as nursing home expenses, tend to rise with age for both decedents 
and  “survivors.” Scitovsky, who examined  nursing  home  as well  as typical 
Medicare-covered services, reported that the decline with age in decedent ex- 
penses for Medicare was largely offset by increases in expenses for noncov- 
ered services (Scitovsky  1988). Recent changes in Medicare reimbursement 
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hospice, and other nonhospital services; these may alter the pattern of expendi- 
tures for decedents in ways that were not apparent during the late 1980s. Such 
expenses may vary by diagnosis, a possibility that we will be able to explore 
with more recent claims files. 
Overall,  our results  confirm  that  decedents  have disproportionately  high 
Medicare expenses. But a comparison with high-cost users suggests that many 
of the characteristics of decedents are similar to those of  high-cost  Medicare 
enrollees who do not die during a given period. This suggests that, at least 
based on the information available in Medicare claims files, it will be difficult 
to formulate policies to limit expenditures for individuals in the last year of 
life without simultaneously limiting health care delivered to sick Medicare re- 
cipients who have the potential to survive. A detailed study of  sophisticated 
mortality prediction models in the severely ill elderly (SUPPORT; Murphy and 
Cluff  1990) implies that more comprehensive clinical information is unlikely 
to change this conclusion. 
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Comment  David M. Cutler 
Garber, MaCurdy, and McClellan have written an interesting paper on medical 
care expenditures at the end of life. It is well known that a lot of medical care 
resources (up to one-third of Medicare dollars) are spent in the last year of life. 
It has also long been suspected that not all of this care is truly necessary. Thus, 
it seems natural to search for cost savings by eliminating unnecessary medical 
expenditures at the end of life. 
Garber et al. cast doubt on the possibility of large savings in end-of-life care. 
They note that the diagnoses  associated with large end-of-life care expendi- 
tures are similar to the diagnoses associated with high spending in general. For 
example, much care at the end of life is provided to patients with pneumonia; 
but pneumonia is not a particularly good indicator that a patient is about to die. 
Thus, it would make little sense to ration care to patients with pneumonia as a 
way of limiting unnecessary end-of-life medical expenses. 
Garber et al. point out valuable facts about end-of-life  expenditures.  The 
ease of deciding to save money through reduced end-of-life care is surely over- 
stated. But the paper is too quick to dismiss potential end-of-life care savings. 
I say this for two reasons. 
The first reason is statistical. While Garber et al. look at medical spending 
by diagnosis, they do not relate medical spending to the underlying disease of 
the patient. Consider a simple observation: a person with severe heart failure 
is more likely to catch pneumonia than a person with a well-functioning heart. 
Garber et al. note that most pneumonia diagnoses are not for people with very 
severe heart failure; therefore, it makes little sense to ration care to patients 
with pneumonia as a way of  saving money for those with severe heart failure. 
But suppose we instead associate the spending on pneumonia for the patient 
with severe heart failure with heart failure itself, rather than with pneumonia. 
Then we might be able to ration care to patients with severe heart failure and 
save money. 
The key issue is whether we want to group spending by immediate diagnosis 
or underlying medical condition. Garber et al. group spending by immediate 
diagnosis. It seems more fruitful, and technically possible, to group spending 
by the underlying condition of the patient. Such a grouping could change views 
about end-of-life care dramatically. 
David M. Cutler is professor of economics at Harvard University and a faculty research fellow 
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The second issue concerns the information that is available to care providers 
versus researchers. Garber et al. find little difference in observable characteris- 
tics between those who are about to die and those farther away from death. My 
impression from talking with physicians is that with more information one can 
do a better job of forecasting death. This is probably not true for all patients: 
for a vast majority of patients, ultimate  survival is not known with any cer- 
tainty. But for some patients, physicians are reasonably sure that the patient 
will die. 
Many of these patients, however, wind up spending a lot of money: they are 
in an ICU for many months, they get intensive surgeries, and they receive many 
diagnostic tests. Often, this care is provided because there is no coordination 
mechanism for dealing with the patient. The patient is not alerted to nonhospi- 
tal alternatives, or physicians who know the wishes of the patient are not pres- 
ent when these decisions are made. Thus, among physicians I have spoken to 
there is a strong sense that substantial resources could be saved for a small 
number of patients who are near death but still receiving intensive treatments. 
This does not mean that we can save a lot of  money for the average patient; 
Garber et al. show that this is not the case. But for many patients, medical care 
is overprovided and society could spend much less without a great deal of loss. 
Eliminating this care could save substantial resources. 